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Abstract: Engineered nanomaterials are increasingly being developed for paints, sunscreens,
cosmetics, industrial lubricants, tyres, semiconductor devices, and also for biomedical applications
such as in diagnostics, therapeutics, and contrast agents. As a result, nanomaterials are being
manufactured, transported, and used in larger and larger quantities, and potential impacts on
environmental and human health have been raised. Poly(amidoamine) (PAMAM) dendrimers are
specifically suitable for biomedical applications. They are well-defined nanoscale molecules which
contain a 2-carbon ethylenediamine core and primary amine groups at the surface. The systematically
variable structural architecture and the large internal free volume make these dendrimers an attractive
option for drug delivery and other biomedical applications. Due to the wide range of applications,
the Organisation for Economic Co-Operation and Development (OECD) have included them in their
list of nanoparticles which require toxicological assessment. Thus, the toxicological impact of these
PAMAM dendrimers on human health and the environment is a matter of concern. In this review,
the potential toxicological impact of PAMAM dendrimers on human health and environment is
assessed, highlighting work to date exploring the toxicological effects of PAMAM dendrimers.
Keywords: PAMAM dendrimers; nanotoxicology; engineered nanoparticle; nanomedicine; toxicology
1. Introduction
Nanotechnology is a new and rapidly emerging field that involves the design, production,
and exploitation of structures at the nanoscale. A nanomaterial is a material that has one or more
external dimensions in the nanoscale or which is nanostructured. A nano-object with all three external
dimensions in the nanoscale is defined as a nanoparticle [1]. Nanotechnology is a sector of the materials
manufacturing industry that has already created a multibillion market which is widely expected to
grow to 4.4 trillion $US by 2018 [2]. Numerous applications of nanoparticles are already on the market,
in products such as paints, sunscreens, cosmetics, self-cleaning glass, industrial lubricants, advanced
tyres, semiconductor devices, medicine, and food [3–5].
In the biomedical field, nanotechnology is also projected to have a significant impact and has
already created a 96.9 billion $US market [4]. For example, polymeric micro and nanoparticles have
been proposed for a wide range of medical applications in terms of diagnosis, tissue engineering, and as
drug delivery devices [6–12]. Several nano-formulations like Doxil (liposome-based nanoparticles),
DaunoXome (PEGylated lipososmal doxorubicin), Myocet (Liposomal daunorubicin), Abraxane
(albumin-bound paclitaxel nanoparticles) have been approved for clinical use and several other
nanoformulations are undergoing clinical trials [13]. Inorganic nanomaterials are being proposed as
imaging probes for magnetic resonance imaging (MRI) [14,15], computed tomography (CT) [16,17],
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and dual-energy mammography (DEM) [18,19]. Polymeric nanomaterials based on US Food
and Drug Administration (FDA) approved polymers such as poly(lactic-co-glycolic acid) (PLGA)
and poly(lactic acid) (PLA) have been proposed as drug delivery vehicles and vaccine delivery
systems [20–23] and for tissue engineering [24].
Dendritic nanoparticles such as poly(amidoamine) (PAMAM) dendrimers have already been
explored for applications such as targeted drug delivery in cancer therapy [25–28], gene delivery [29–31],
medical imaging applications [32–35], and also the mannosylated form of PAMAM dendrimers has been
proposed for vaccine delivery systems [36].
2. Toxicology of Engineered Nanoparticles
Nanotoxicology is an evolving sub-specialty of particle toxicology. It addresses the toxicology
of nanoparticles, which in general appear to elicit specific biological responses that are governed by
their nano-size which absent in bulk form. The proliferation of nanotechnology, as well as increase in
the anthropogenic nanoparticulate matter has prompted concerns over the safety of these nano-sized
particles per se, that may have either intentional or occupational exposure to human or the environment.
Therefore, it is important to understand the interaction of nanomaterials with living organisms in
terms of potential toxicological impacts on both the environment and human health.
Nanotoxicology was mostly focused on individual studies, with one to a few nanomaterials, on the
biological interaction of nanoparticles without greater integration and coherence among them [37–46].
However, more recently bigger consortia have been formed, e.g., EU sponsored FP7-NANOREG
project etc., with integrated and harmonised approaches for screening of a wide range of nanomaterials
in parallel with different biological models using standardised protocols [47]. Physico-chemical
characteristics of the nanoparticles such as particle size, surface area, surface charge and morphology
have been identified as important factors in determining their toxic effects [39,45,48–50] and the
importance of appropriate characterisation of these properties has been highlighted [51]. The smaller
a particle is, the larger its surface area to volume ratio is, and thus the associated chemical and
biological activity of the material is increased. The greater chemical reactivity of nanomaterials
results, for example, in increased production of reactive oxygen species (ROS) [50,52], including
free radicals. In the case of nanotoxicology, increased levels of intracellular ROS as a result of
nanoparticle exposure have been identified as a fundamental precursor to inflammation, genotoxicity,
and apoptosis [53]. Oxidative stress induces signaling pathways of MAPK and transcription factors
such as NFkB, AP-1 [54–56]. These transcription factors induce mRNA expression of pro-inflammatory
mediators, finally causing inflammation. Persistent inflammation can lead to cell damage, induced by
chemical/physical injury, anoxia, or nanoparticles. When nanoparticles enter into the bloodstream,
they immediately encounter a complex environment of plasma proteins and immune cells [57].
In addition, some nanoparticles seem to be able to translocate from their site of deposition to more
remote sites such as brain [58,59]. Notably, toxicity of the engineered nanoparticles is dependent upon
the surface coating materials; in a recent study of gold nanoparticles, it was observed that the in vitro
toxicity was due to the coating materials rather than exposure dose or time [60].
In addition to potential human hazards, the effect of nanoparticles on the environment should also
be considered. The assessment of adverse environmental effects of nanoparticles requires a detailed
understanding, for example, mobility, reactivity, toxicity, and bio-persistence in the environment [61].
Over the last decade, an increasing number of ecotoxicological studies of engineered nanomaterials
have emerged in the literature. Many studies have focused on carbon based material [62–68], various
metallic nanoparticles (e.g., silver, zinc, cadmium, iron oxide, etc.) [69–71], as well as polymeric
nanoparticles (e.g., dendrimers) [48,49,72]. Carbon based materials, such as carbon nanotubes,
have been investigated in a wide range of ecological organisms, such as algae [73], daphnia [74],
and fish [75]. Ecotoxicity of metallic nanoparticles, such as silver nanoparticles, have been also
been investigated [76–79]. Oprsal et al. reported that the toxicity of silver nanoparticles was due
to bioaccumulation of sedimented silver nanoparticle aggregates in the fish model and therefore
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an increase in the local silver concentration can be responsible for the toxicity [79]. Ramskov et al.,
reported that, in invertebrate sediment dwelling organism, the bioaccumulation was much higher
in worms than in snails, which can be due to sediment avoidance behavior of the snail species [78].
However, the toxicity, in terms of growth and mortality, of silver nanoparticles also differed among the
worm species used in this study. Such a species-specific effect is likely related to differences in uptake
route, internalization, and detoxification capacity.
3. PAMAM Dendrimers
PAMAM dendrimers are well-defined nanoscale constructs, originally synthesised by Tomalia et al.,
and have a range of potential novel applications in the biomedical field [80]. PAMAM dendrimers
contain a 2-carbon ethylenediamine core and for each increase of generation, by a stepwise synthesis,
the effective surface charge, molecular weight, and size increases systematically. With increasing
generation, the number of surface amine groups increases, while the distance between the surface
charges decreases, which helps to seal the interior from the bulk solution [81]. These properties can be
useful to enhance the encapsulation and release of different drugs from the dendrimers. The quantity
of entrapped guest molecules depends upon their size and shape, as well as size of the dendrimer’s
internal cavities. It has been proposed that these dendrimers can be opened under controlled conditions
to release entrapped drug molecules by partial or total hydrolysis [82–84]. Thus, the systematically
variable structural architecture and the large internal free volume make these dendrimers an attractive
option for drug delivery and other biomedical applications [85–88].
Kannan et al. have reviewed the development of dendrimer based applications in nanomedicine,
describing the evolution of polymer based nanomedicine as well as the challenges to advancing
nanomedicine/therapies into clinical trials and legislative approval. In terms of critical nanoscale
design parameters, they advocate the use of dendritic nanoparticles as their functions involving
PKs, PDs, drug delivery strategies, excretion modes, biodistribution patterns, biocompatibility,
and nanotoxicology can readily be optimised, and describe the state of the art of dendrimer-based
in vivo therapies [89].
It is also possible to passively target PAMAM dendrimers to a tumor because of the increased
permeability of tumor vasculature to macromolecules and also due to the limited lymphatic
drainage [90]. The unique properties of dendrimers, as compared to linear polymers, render them of
interest for intracellular drug delivery system for cancer therapy [91]. PAMAM dendrimers have also
been proposed for tumor targeting using FDA-approved antibodies, such as trastuzumab [92–94] and
cetuximab [95,96], against epidermal growth factors.
Amine terminated PAMAM dendrimers have been shown to enhance anti-ovalbumin
immunoglobulin-G and immunoglobulin-M levels and have also been used as adjuvants in
vaccine delivery systems [97]. N-acetyl-D-glucosamine modified PAMAM dendrimers improve the
immunogenicity by upregulation of antibody formation via activation of natural killer cells [98].
Another study showed that PAMAM dendrimers of the mannosylated form potentiate the
immunogenicity and they have been proposed for vaccine delivery systems [36].
PAMAM dendrimers are also well documented for the application in magnetic resonance imaging
(MRI) using Gd-radiolabeled PAMAM dendrimers with DTPA chelate [99]. Using PAMAM dendrimers
as a vehicle, Gd-DTPA-PAMAM dendrimers increase the longitudinal relaxation (r2 relaxivity) which
improves the MR signal in the surrounding tissue. Also, it has been reported that conjugation of
Gd-DTPA with PAMAM dendrimers improves the stability of the Gd-DTPA complex and reduces
renal toxicity due to free gadolinium, which was observed in free Gd-DTPA (Magnevist®). It has
also been shown that folate-conjugated PAMAM-Gd significantly improves the tumor targeting and
increases the MR signal in the tumor [100].
Notably, however, in recent times, the number of articles on the topic of nanoparticle toxicity,
PAMAM dendrimers, and PAMAM dendrimer toxicity published and cited has been increasing
daily (Figure 1). While much of the published research has focused on in vitro or in vivo toxicity of
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nanoparticles, while studies of environmental impacts, or ecotoxicity, have only more recently begun
to emerge.
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3.1. I itro oxicological t dies of A A Dendrimers
3.1.1. In Vitro Mammalian Toxicological Studies
The wide range of proposed applications of PAMAM dendrimers merit an assessment of the
environmental health risk and indeed the OECD has identified that there is an urgent need of
study of the human and environmental related toxicity of dendritic polymer nanoparticles [101].
Cytotoxicological assessment of the PAMAM dendrimers (G4, G5, and G6) has indicated adverse
effects to mammalian cells in vitro in a dose dependent manner [45,72,102–104]. A recent study shows
that the pathway of the toxic response induced by PAMAM dendrimers is by apoptosis mediated by
mitochondrial dysfunction [105]. Studies by other groups reported that PAMAM dendrimers contribute
to reduction of transmembrane potential and hinder the influx of Ca2+ ions to the mitochondria [106]
and PAMAM dendrimers have been shown to induce membrane disruption, including formation
of holes and membrane erosion in supported lipid bilayaers [107–109]. The toxicity of PAMAM
dendrimers in mammalian cells has been demonstrated to depend upon the generation and number of
surface functional groups [45,49,72,102–104,110–112]. The positively charged surface functional groups
of PAMAM dendrimers are responsible for the toxicity and destabilise the cell membrane and cause
cell lysis [113]. Although systematic studies of the generation dependent toxicity extending to higher
and lower generation number have not been reported, systematic studies of the structurally related
poly(propylene imine) (PPI) dendrimers indicated that the lower generations (G0–G2) are uptaken
passively rather than actively and are non-toxic to mammalian cells, indicating the importance of the
cellular uptake mechanism [114].
In mouse macrophage cells, it was observed that PAMAM dendrimers (G4, G5, and G6) produce
a dose and generation dependent cytotoxicity and the toxicity correlated with the number of surface
amine groups per generation [42]. The mechanism of the toxicity is due to the generation of intracellular
reactive oxygen species (ROS) which leads to a cascade of secretion of pro-inflammatory markers and
finally cell death (Figure 2). In human skin and intestinal cells, the toxicity of PAMAM dendrimers was
Int. J. Environ. Res. Public Health 2018, 15, 338 5 of 18
also seen to be dependent upon the exposure dose and generation of PAMAM dendrimers using four
different assays, MTT, alamar blue, neutral red, and the clonogenic assay [103]. Following preliminary
cytotoxicity investigation, the toxicity mechanism of PAMAM dendrimers was explored and it was
observed that PAMAM dendrimers are localised in the early endosomes/lysosomes but can then
migrate to mitochondria upon lysis of the endosome/lysosomes [105]. A biphasic ROS generation
profile was observed, the earlier associated with the localisation in the endosomes, the later in the
mitochondria. The mechanisms of subsequent cellular responses leading to inflammatory responses,
apoptosis, and cell death have been proposed and modelled using a phenomenological rate equation
approach [45,72,102,115]. A comparative toxicity study of PAMAM and lipid-PAMAM was reported
recently by Bertero et al., wherein they showed that both the dendrimer forms are able to enter
into endothelial and primary neural cells. However, only the PAMAM dendrimers induced a toxic
response [116]. Another study of PAMAM G4 and G4-C12 modified PAMAM dendrimers was carried
out in primary neural cells. G4-C12 modified PAMAM (at 100 nM concentration) has an adverse
effect on the primary neural cell in vitro, whereas PAMAM G4 does not induce apoptotic cell death at
sub-micromolar concentrations [117]. Cationic PAMAM dendrimers have been reported to cause cell
cycle arrest in primary human lung cell line at low (noncytotoxic) dose, but not in lung-derived cancer
cells [118]. Transcriptomics analysis andβ-galactosidase staining suggested that PAMAM at this low
dose also induced senescence in the primary lung cells. In contrast, hydroxyl functionalised PAMAM
dendrimers did not show any such effect on cell cycle progression in this study.
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Figure 2. Panel (A), dose depend cytotoxicity effect of PAMAM dendrimer in J774A.1; cytotoxicity
assay was performed via alamar blue (AB) and MTT assay. The concentration ranges used for the
cytotoxicity assays with G4, G5, and G6 were 0.08 µM to 6 µM; 0.03 µM to 2 µM; and 0.013 µM to 1 µM
respectively, as determined from an initial range finding study. Panel (B), Confocal laser scanning
micrographs of intracellular ROS generation in J774A.1 cells, following exposure to negative control,
positive control (H2O2), PAMAM G-4, PAMAM G-5, and PAMAM G-6. The data are shown after
a 2 h exposure of PAMAM dendrimers. Panel (C), graphical representation of different responses as
a function of time. Figure reproduced with permission from reference [45].
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3.1.2. Physicochemical Properties of PAMAM Dendrimers versus Toxicity
The surface coating has been seen to determine the cytotoxicity/biocompatibility for many
nanoparticles [119]. In the case of PAMAM dendrimers, the toxicity is largely due to the surface amine
groups, and several studies have reported that after surface modification (resulting in neutral or anionic
surfaces) the toxicity of PAMAM dendrimers can be reduced. A number of studies have explored the
underlying mechanisms of this dependence of the toxic response on dendrimer surface properties.
G2 and G3 of the cationic phosphorous dendrimer have been tested in murine embryonic
hippocampal cells (mHippoE-18) and both dendrimers induce mHippoE-18 cell death by generation
of reactive oxygen species, alteration of the mitochondrial membrane potential, changes in cell cycle
phase, and DNA damage [120]. Cationic PAMAM dendrimers are haemolytic and cytotoxic, depending
on the molecular weight, number of surface amine groups, and generation of PAMAM dendrimers;
whereas anionic PAMAM dendrimers and PEO modified CSi-PEO dendrimers are neither haemolytic
nor cytotoxic [110]. Another study demonstrated the effect of surface functionality of PAMAM
dendrimers on enzyme activity. In this study, cationic (G4 PAMAM –NH2), neutral (G4 PAMAM –OH),
and carboxylated (G3.5 PAMAM –COOH) dendrimers were employed. It was seen that positively and
neutral charged PAMAM dendrimers inhibit the enzyme activity of pepsin, whereas negatively charge
PAMAM dendrimers have no effect of enzyme inhibition [121]. Surface modification of G5 PAMAM
dendrimer with zwitterionic carboxybetamine was seen to reduce the toxic effect of dendrimers [122].
Similar surface modification of G4 PAMAM dendrimer with 4-carbomethoxypyrrolidone reduced
the toxicity in terms of intracellular ROS generation and alteration of mitochondrial membrane
potential [123]. When the surface of PAMAM G4 is modified with dimethyl itaconate, resulting
in pyrrolidone at the PAMAM surface, it was found that no haemolytic effect was observed [124].
PEGylation also dramatically reduced the haemolytic effect of PAMAM dendrimers [113] and another
study reported that systematic replacement of the surface amine groups with acetyl groups in PAMAM
dendrimers resulted in a 10-fold reduction of the toxicity [125].
3.1.3. Cellular Uptake and Biodegradation
Due to smaller size of nanoparticles, including dendrimers, they are likely to use a range
of cellular machinery for internalisation and trafficking to various sub-cellular compartments.
The pH also varies in different subcellular compartments of the cell, as well as, in different organs.
The pH becomes more acidic successively from endocytic vesicles to early endosomes (pH 6.5),
late endosomes, and lysosomes (pH < 5.5) [126]. Seib et al. have shown that PAMAM can enter
the cells by endocytosis [127], while Lee et al. reported that the configuration of dendrimers is
dependent on the pH of the surrounding [128]. Differences in cellular uptake mechanisms may
exist depending on the surface properties. For instance, in A549 lung epithelial cells (a cancer
cell line) anionic G3.5-carboxyl-terminated PAMAM were shown to mainly be taken up by
caveolae-mediated endocytosis, whereas hydroxyl and amine terminated G4 PAMAM were taken
up by a non-clathrin-dependent mechanism [129]. Albertazzi et al. demonstrated that dendrimers
are internalised by both clathrin-dependent endocytosis and macropinocytosis in HeLa cells and
are eventually delivered to the lysosomal compartment [130]. Overall, understanding the stability of
dendrimers at different pH values is important as this will aid in the understanding of their intracellular
fate and, hence, in their utility as drug delivery vehicles or as imaging probes. The biocompatibility of
dendrimers must be accompanied by a fast renal elimination, excretion, or by biodegradation, while the
degradation products must be non-toxic [80,131]. Commercially available PAMAM dendrimers are
reported to be relatively resistant to hydrolysis [132]. Feliu et al. reported that hydroxyl terminated
2,2-bis(methylol)propionic acid dendrimers (bis-MPA) are degradable at physiological pH (7.5) but
not at acidic pH (4.5) (no degradation after 40 days), indicating the stability increases at low pH.
These dendrimers were also found to be non-cytotoxic to HeLa, THP.1 cell lines and also to primary
human macrophages [131].
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Recent studies have demonstrated that, when immortalised, non-cancerous human keratinocyte
(HaCaT) cells were treated with DL-Buthionine-(S,R)-sulfoximine (BSO), the active uptake of PAMAM
dendrimers was suppressed, and when passively uptaken, the dendrimers act as anti-oxidants, rather
than oxidants, eliminating the initial phase of endocytosis associated oxidative stress contribution
to the toxic response [133]. BSO has previously been employed to study the effects of the reduction
of levels of the intracellular antioxidant glutathione (GSH); and therefore oxidative stress [134–137],
but has also been shown to cause membrane permeabilisation. The increased permeability of the
membrane allows passive uptake of the dendrimers, by passing the endocytosis pathway [138]. Notably,
in a study by Khalid et al. while the larger, higher generations of the aminated nanoscale dendrimers
poly(propylene imine) (PPI) were demonstrated to elicit oxidative stress and significant toxicity,
the smaller, lower generations exhibited intracellular antioxidant behaviour and low toxicity [114].
Importantly, these studies highlight that the process of endosomal digestion of the dendrimers in itself
contributes significantly to the toxic response. As a strategy for drug release, endosomolysis can be
extremely disruptive to the cell [102] and therefore, in the case of cationic nanoparticles for intracellular
nanomedical applications, avoiding the process of endocytosis may be a valid strategy to pursue [139].
In terms of therapeutic applications, direct entry into the cytosol may be a more convenient route for
drug or gene delivery.
3.1.4. In Vitro Eco Toxicological Studies
As well as potential hazards of human exposure, the increased use of dendrimers in a range
of nanomedical applications increases the risks of environmental exposure, warranting a thorough
investigation of potential ecotoxicological impacts of these materials. Although such studies are
limited, the results are consistent with those observed for human based studies.
As in the case of in vitro cytotoxicological studies in mammalian systems, a systematic dose and
generation dependent toxicological response was observed in fresh water ecological organisms [49].
Rainbow trout gonadal fish cell-line (RTG-2) was seen to be the least sensitive to the PAMAM
dendrimers [49]. Toxicity was found to be generation dependent in each test organism; the toxicity
order is G6 > G5 > G4. Among the two fish cell lines used, PLHC-1 (Poeciliopsis lucida hepatocarcinoma
cells) is more sensitive than RTG-2. Furthermore, the toxic mechanism of PAMAM dendrimers was
investigated in the fish cell line (PLHC-1) by Naha et al. and the results suggested that the toxicity
is initiated by the generation of reactive oxygen species, followed by DNA damage and cell death
(Figure 3) [72]. The generation of ROS and DNA damage is related to the number of surface amine
group and dendrimer generation [72]. As the envisioned applications of PAMAM dendrimers are in
low dose nanomedical applications, it is expected that the release the environment through domestic
or even clinical waste will be very low. However, a greater potential exposure risk may be presented
through industrial effluent from the source manufacturers, and so a risk management strategy should
be established.
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3.2. In Vivo Toxicological Studies of PAMAM Dendrimers
In vivo toxicity of PAMAM dendrimers has barely been explored. In this section, the potential
adverse effects of PAMAM dendrimers demonstrated in different test model (zebrafis , mice, rat,
r bbit model, etc.) are highlighte .
Recently, an in vivo study claimed that cationic dendrimers induced fibrinogen aggregates and
formation of clots in blood vessels in a zebr fish model when injected intravenously (Figure 4). In this
study, PAMAM G7 was injected intravenously into zebrafish, a d it was found that PAMAM G7
dendrimers induce aggregatio of many blood protei s, such as fibrinogen, albumin, etc. Most of
the blood protei s have negative surface charge, and therefore cationic d drimers aggressively
int ract with th m and form blood clots (Figure 4) [140]. A furth r study in a rodent model show d
the formation of bloo clots after intraveno s injection of PAMAM endrimers [141]. Therefor ,
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intravenous administration of these cationic dendrimers is not safe for therapeutic applications.
Surface modification is imperative to make the dendrimer biocompatible [87,123,124,142].
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c lls trapped inside the vessel, while the large whi e arrows show signific nt blood clots inside the
vessels. Notice in (E) that the caudal artery is comple ely occlude with no observabl flow in the
major caudal ein. Figure reproduced with permission from reference [140].
Another study in a mouse model showed that PAMAM dendrimer G-5 can cause acute lung
failure when administered via the intranasal route. The mechanism of this adverse effect is via bindi
of the PAMAM de drimer to the angiotensin-converting enzyme 2, downregulating its function
and expression in lung tissue. This results i der gulati of the r in-angiotensi system [143].
Furthermore, a study on PAMAM G4 and G4-C12 modified PAMAM dendrimers i a mouse model
show d that both dendrimer forms are able to penetrate into neurons after intra-ventricular injection.
PAMAM G4 does not induc apoptotic cell d a h at sub-micromolar c centratio s, but ind ces
low microglia activation in the brain tissue after a we k [117]. A re ent study by Durocher and
Girard has shown pro-inflammatory activities of PAMAM dendrimers (G0–G3) i vivo using a murine
ir pouch model. They found that PAMAM dendrimers rapi ly increased leukocyte nflux after
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3 h, the vast majority of cells being neutrophils. In addition, they observed the production of
several cytokines/chemokines. The pro-inflammatory activities were correlated with the dendrimer
generation, i.e., G3 > G2 > G1 > G0 [144].
Notably, an interesting study by Heiden et al. reported that amine terminated PAMAM
dendrimers adversely affect the growth and development of zebrafish embryos (Figure 5) at sub-lethal
concentrations [145]. In this study, PAMAM G-4 and G-3.5 were investigated, and the results suggested
that cationic PAMAM dendrimers significantly inhibit the development of zebrafish embryos compared
to anionic PAMAM dendrimers. Both in vitro and in vivo toxicity studies on PAMAM dendrimers
revealed that amine terminated PAMAM dendrimers produce higher levels of toxicity than hydroxyl
or carboxylic acid terminated PAMAM dendrimers. Surface modification can therefore enhance the
biocompatibility of PAMAM dendrimers. Another interesting study by Bodewein et al. reported
the toxic effect of PAMAM and PPI dendrimers in a zebrafish embryo model. They did not observe
zebrafish embryo toxicity with anionic PAMAM dendrimers, although exposure to doses greater than
50 µM caused adverse effects to aquatic organisms [112].
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Figure 5. Representative micrographs of overt toxicity seen in zebrafish embryos exposed to control or
2 µM G4 dendrimers beginning at 6 h post fertilization (hpf). All micrographs were taken at 28 hpf.
(A) Control embryo manually removed from chorion (magnification 3.2×). (B) G4 dendrimer-treated
embryo manually removed from chorion (3.2×). (C) Higher magnification of tail of control embryo
(10×). (D) Higher magnification of tail of G4 dendrimer-treated embryo (10×). (E) Mortality of
zebrafish embryos at 120 hpf following exposure to G4 and G3.5 PAMAM dendrimers from 6 to 120 h
post fertilization (hpf). Figure reproduced with permission from [145].
Biodistribution studies are essential to understand and explore the organ specific toxicity effect of
PAM dendrimers. A study in a rabbit model reported the biodistribution of PAMAM dendrimers
(hydroxyl terminated generation 4), and the results suggested that a significant amount of PAMAM
dendrimers is accumulated in the liver, lungs, kidney, and heart. Some dendrimers were also found in
the brain of neonatal rabbit with cerebral palsy [146], whereas no PAMAM dendrimers were found
in the brain of healthy rabbit. Another study in a mouse model reported the oral bioavailability of
PAMAM dendrimer G-6.5, and the results demonstrated that, after oral administration, a substantial
amount of PAMAM dendrimers was found in the heart, lungs, liver, blood, urine, stomach, and small
and large intestine. The presence of PAMAM dendrimers in blood, liver, and urine suggested that
PAMAM G-6.5 crosses the intestinal barrier and reaches the systemic circulation, hence enhancing the
oral bioavailability [147]. Organ specific toxicity studies on PAMAM dendrimers have been barely
explored, and further more in-depth histopathological studies on each organ need to be undertaken,
due to the safety concerns.
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4. Conclusions
PAMAM dendrimers are well-defined nanomaterials of great interest for biomedical applications
such as drug delivery system, in diagnostics and in imaging. In this review, the current information of
the PAMAM dendrimers toxicity in different models has been detailed. In summary, amine terminated
PAMAM dendrimers induce toxicity in the range of models discussed above. Furthermore, the toxic
response increases systematically with generation, correlated with the number of surface amine
groups. However, hydroxyl (–OH) and carboxylic acid (–COOH) terminated PAMAM dendrimers
have been shown to be significantly less toxic. The importance of surface modification is highlighted,
which improves the biocompatibility of the amine terminated PAMAM dendrimers. This is
beneficial for the design of biocompatible dendrimers for biomedical applications. However,
the pharmacokinetics, biodistribution, biodegradation, and chronic toxicity of PAMAM dendrimers
are not yet clearly understood. Further studies in this area are sorely needed for the development of
biocompatible dendrimers for biomedical applications.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. European Commission. Available online: http://ec.europa.eu/environment/chemicals/nanotech/faq/
definition_en.htm (accessed on 5 February 2018).
2. Luxresearch. Available online: https://portal.luxresearchinc.com/research/report_excerpt/16215 (accessed
on 5 February 2018).
3. Garland, A. The Global Market for Carbon Nanotubes to 2015. 2009. Available online: http://www.
nanoposts.com/indx.php?mod=nanotube (accessed on 20 March 2011).
4. Pattni, B.S.; Chupin, V.V.; Torchilin, V.P. New Developments in Liposomal Drug Delivery. Chem. Rev. 2015,
115, 10938–10966. [CrossRef] [PubMed]
5. Nanotechnology. Available online: http://www.nanotechproject.org/cpi/ (accessed on 5 February 2018).
6. Ito, F.; Fujimori, H.; Honnami, H.; Kawakami, H.; Kanamura, K.; Makino, K. Effect of polyethylene glycol on
preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique. Colloids
Surf. B Biointerfaces 2008, 66, 65–70. [CrossRef] [PubMed]
7. Naha, P.C.; Kanchan, V.; Manna, P.K.; Panda, A.K. Improved bioavailability of orally delivered insulin using
Eudragit-L30D coated PLGA microparticles. J. Microencapsul. 2008, 25, 248–256. [CrossRef] [PubMed]
8. Naha, P.C.; Kanchan, V.; Panda, A.K. Evaluation of parenteral depot insulin formulation using PLGA and
PLA microparticles. J. Biomater. Appl. 2009, 24, 309–325. [CrossRef] [PubMed]
9. Storrie, H.; Mooney, D.J. Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering.
Adv. Drug Deliv. Rev. 2006, 58, 500–514. [CrossRef] [PubMed]
10. Naha, P.C.; Byrne, H.J.; Panda, A.K. Role of Polymeric Excipients on Controlled Release Profile of Glipizide
from PLGA and Eudragit RS 100 Nanoparticles. J. Nanopharm. Drug Deliv. 2013, 1, 74–81. [CrossRef]
11. Gao, L.; Liu, Y.; Kim, D.; Li, Y.; Hwang, G.; Naha, P.C.; Cormode, D.P.; Koo, H. Nanocatalysts promote
Streptococcus mutans biofilm matrix degradation and enhance bacterial killing to suppress dental caries
in vivo. Biomaterials 2016, 101, 272–284. [CrossRef] [PubMed]
12. Thaxton, C.S.; Rink, J.S.; Naha, P.C.; Cormode, D.P. Lipoproteins and lipoprotein mimetics for imaging and
drug delivery. Adv. Drug Deliv. Rev. 2016, 106, 116–131. [CrossRef] [PubMed]
13. Cheng, Z.; Al Zaki, A.; Hui, J.Z.; Muzykantov, V.R.; Tsourkas, A. Multifunctional nanoparticles: Cost versus
benefit of adding targeting and imaging capabilities. Science 2012, 338, 903–910. [CrossRef] [PubMed]
14. Naha, P.C.; Zaki, A.A.; Hecht, E.; Chorny, M.; Chhour, P.; Blankemeyer, E.; Yates, D.M.; Witschey, W.R.;
Litt, H.I.; Tsourkas, A.; et al. Dextran coated bismuth-iron oxide nanohybrid contrast agents for computed
tomography and magnetic resonance imaging. J. Mater. Chem. B Mater. Biol. Med. 2014, 2, 8239–8248.
[CrossRef] [PubMed]
15. Pierre, V.C.; Harris, S.M.; Pailloux, S.L. Comparing Strategies in the Design of Responsive Contrast Agents
for Magnetic Resonance Imaging: A Case Study with Copper and Zinc. Acc. Chem. Res. 2018. [CrossRef]
[PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 338 12 of 18
16. Bernstein, A.L.; Dhanantwari, A.; Jurcova, M.; Cheheltani, R.; Naha, P.C.; Ivanc, T.; Shefer, E.; Cormode, D.P.
Improved sensitivity of computed tomography towards iodine and gold nanoparticle contrast agents via
iterative reconstruction methods. Sci. Rep. 2016, 6, 26177. [CrossRef] [PubMed]
17. Kim, T.; Lee, N.; Arifin, D.R.; Shats, I.; Janowski, M.; Walczak, P.; Hyeon, T.; Bulte, J.W.M. In Vivo Micro-CT
Imaging of Human Mesenchymal Stem Cells Labeled with Gold-Poly-L-Lysine Nanocomplexes. Adv. Funct.
Mater. 2017, 27. [CrossRef] [PubMed]
18. Karunamuni, R.; Naha, P.C.; Lau, K.C.; Al-Zaki, A.; Popov, A.V.; Delikatny, E.J.; Tsourkas, A.; Cormode, D.P.;
Maidment, A.D. Development of silica-encapsulated silver nanoparticles as contrast agents intended for
dual-energy mammography. Eur. Radiol. 2016, 26, 3301–3309. [CrossRef] [PubMed]
19. Naha, P.C.; Lau, K.C.; Hsu, J.C.; Hajfathalian, M.; Mian, S.; Chhour, P.; Uppuluri, L.; McDonald, E.S.;
Maidment, A.D.; Cormode, D.P. Gold silver alloy nanoparticles (GSAN): An imaging probe for breast
cancer screening with dual-energy mammography or computed tomography. Nanoscale 2016, 8, 13740–13754.
[CrossRef] [PubMed]
20. Anish, C.; Goswami, D.G.; Kanchan, V.; Mathew, S.; Panda, A.K. The immunogenic characteristics associated
with multivalent display of Vi polysaccharide antigen using biodegradable polymer particles. Biomaterials
2012, 33, 6843–6857. [CrossRef] [PubMed]
21. Gupta, R.K.; Goswami, D.G.; Singh, R.R.; Surolia, A.; Panda, A.K. Soybean agglutinin coated PLA particles
entrapping candidate vaccines induces enhanced primary and sustained secondary antibody response from
single point immunization. Eur. J. Pharm. Sci. 2012, 45, 282–295. [CrossRef] [PubMed]
22. Kanchan, V.; Katare, Y.K.; Panda, A.K. Memory antibody response from antigen loaded polymer particles
and the effect of antigen release kinetics. Biomaterials 2009, 30, 4763–4776. [CrossRef] [PubMed]
23. Kanchan, V.; Katare, Y.K.; Panda, A.K. Role of alum in improving the immunogenicity of biodegradable
polymer particle entrapped antigens. Eur. J. Pharm. Sci. 2009, 38, 18–28. [CrossRef] [PubMed]
24. Rajmohan, G.; Admane, P.; Anish, C.; Panda, A.K. Fusion and self-assembly of biodegradable polymer
particles into scaffoldlike and membranelike structures at room temperature for regenerative medicine.
Mol. Pharm. 2014, 11, 2190–2202. [CrossRef] [PubMed]
25. Yoon, A.R.; Kasala, D.; Li, Y.; Hong, J.; Lee, W.; Jung, S.J.; Yun, C.O. Antitumor effect and safety profile of
systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in
orthotopic lung tumor model. J. Controll. Release 2016, 231, 2–16. [CrossRef] [PubMed]
26. Yuan, A.; Yang, B.; Wu, J.; Hu, Y.; Ming, X. Dendritic nanoconjugates of photosensitizer for targeted
photodynamic therapy. Acta Biomater. 2015, 21, 63–73. [CrossRef] [PubMed]
27. Mohammadpour, R.; Safarian, S.; Buckway, B.; Ghandehari, H. Comparative Endocytosis Mechanisms and
Anticancer Effect of HPMA Copolymer- and PAMAM Dendrimer-MTCP Conjugates for Photodynamic
Therapy. Macromol. Biosci. 2017, 17. [CrossRef] [PubMed]
28. Heyder, R.S.; Zhong, Q.; Bazito, R.C.; da Rocha, S.R.P. Cellular internalization and transport of biodegradable
polyester dendrimers on a model of the pulmonary epithelium and their formulation in pressurized
metered-dose inhalers. Int. J. Pharm. 2017, 520, 181–194. [CrossRef] [PubMed]
29. Li, J.; Chen, L.; Liu, N.; Li, S.; Hao, Y.; Zhang, X. EGF-coated nano-dendriplexes for tumor-targeted nucleic
acid delivery in vivo. Drug Deliv. 2016, 23, 1718–1725. [PubMed]
30. Venuganti, V.V.; Saraswathy, M.; Dwivedi, C.; Kaushik, R.S.; Perumal, O.P. Topical gene silencing by
iontophoretic delivery of an antisense oligonucleotide-dendrimer nanocomplex: The proof of concept in
a skin cancer mouse model. Nanoscale 2015, 7, 3903–3914. [CrossRef] [PubMed]
31. Zheng, W.; Cao, C.; Liu, Y.; Yu, Q.; Zheng, C.; Sun, D.; Ren, X.; Liu, J. Multifunctional polyamidoamine-
modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal
multidrug resistance. Acta Biomater. 2015, 11, 368–380. [CrossRef] [PubMed]
32. Boni, A.; Bardi, G.; Bertero, A.; Cappello, V.; Emdin, M.; Flori, A.; Gemmi, M.; Innocenti, C.; Menichetti, L.;
Sangregorio, C.; et al. Design and optimization of lipid-modified poly(amidoamine) dendrimer coated
iron oxide nanoparticles as probes for biomedical applications. Nanoscale 2015, 7, 7307–7317. [CrossRef]
[PubMed]
33. Kobayashi, H.; Brechbiel, M.W. Nano-sized MRI contrast agents with dendrimer cores. Adv. Drug Deliv. Rev.
2005, 57, 2271–2286. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 338 13 of 18
34. Opina, A.C.; Wong, K.J.; Griffiths, G.L.; Turkbey, B.I.; Bernardo, M.; Nakajima, T.; Kobayashi, H.; Choyke, P.L.;
Vasalatiy, O. Preparation and long-term biodistribution studies of a PAMAM dendrimer G5-Gd-BnDOTA
conjugate for lymphatic imaging. Nanomedicine 2015, 10, 1423–1437. [CrossRef] [PubMed]
35. Wen, S.; Li, K.; Cai, H.; Chen, Q.; Shen, M.; Huang, Y.; Peng, C.; Hou, W.; Zhu, M.; Zhang, G.; et al.
Multifunctional dendrimer-entrapped gold nanoparticles for dual mode CT/MR imaging applications.
Biomaterials 2013, 34, 1570–1580. [CrossRef] [PubMed]
36. Sheng, K.-C.; Kalkanidis, M.; Pouniotis, D.S.; Esparon, S.; Tang, C.K.; Apostolopoulos, V.; Pietersz, G.A.
Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo.
Eur. J. Immunol. 2008, 38, 424–436. [CrossRef] [PubMed]
37. Bhattacharya, K.; Naha, P.C.; Naydenova, I.; Mintova, S.; Byrne, H.J. Reactive oxygen species mediated DNA
damage in human lung alveolar epithelial (A549) cells from exposure to non-cytotoxic MFI-type zeolite
nanoparticles. Toxicol. Lett. 2012, 215, 151–160. [CrossRef] [PubMed]
38. Brown, D.M.; Donaldson, K.; Borm, P.J.; Schins, R.P.; Dehnhardt, M.; Gilmour, P.; Jimenez, L.A.; Stone, V.
Calcium and ROS-mediated activation of transcription factors and TNF-alpha cytokine gene expression in
macrophages exposed to ultrafine particles. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286, L344–L353.
[CrossRef] [PubMed]
39. Brown, D.M.; Wilson, M.R.; MacNee, W.; Stone, V.; Donaldson, K. Size-dependent proinflammatory effects
of ultrafine polystyrene particles: A role for surface area and oxidative stress in the enhanced activity of
ultrafines. Toxicol. Appl. Pharmacol. 2001, 175, 191–199. [CrossRef] [PubMed]
40. Colvin, V.L. The potential environmental impact of engineered nanomaterials. Nat. Biotechnol. 2003, 21,
1166–1170. [CrossRef] [PubMed]
41. Davoren, M.; Herzog, E.; Casey, A.; Cottineau, B.; Chambers, G.; Byrne, H.J.; Lyng, F.M. In vitro toxicity
evaluation of single walled carbon nanotubes on human A549 lung cells. Toxicol. In Vitro 2007, 21, 438–448.
[CrossRef] [PubMed]
42. Herzog, E.; Casey, A.; Lyng, F.M.; Chambers, G.; Byrne, H.J.; Davoren, M. A new approach to the toxicity
testing of carbon-based nanomaterials—The clonogenic assay. Toxicol. Lett. 2007, 174, 49–60. [CrossRef]
[PubMed]
43. Jeng, H.A.; Swanson, J. Toxicity of metal oxide nanoparticles in mammalian cells. J. Environ. Sci. Health Part A
2006, 41, 2699–2711. [CrossRef] [PubMed]
44. Naha, P.C.; Bhattacharya, K.; Tenuta, T.; Dawson, K.A.; Lynch, I.; Gracia, A.; Lyng, F.M.; Byrne, H.J.
Intracellular localisation, geno- and cytotoxic response of polyN-isopropylacrylamide (PNIPAM)
nanoparticles to human keratinocyte (HaCaT) and colon cells (SW 480). Toxicol. Lett. 2010, 198, 134–143.
[CrossRef] [PubMed]
45. Naha, P.C.; Davoren, M.; Lyng, F.M.; Byrne, H.J. Reactive oxygen species (ROS) induced cytokine production
and cytotoxicity of PAMAM dendrimers in J774A.1 cells. Toxicol. Appl. Pharmacol. 2010, 246, 91–99. [CrossRef]
[PubMed]
46. Vevers, W.F.; Jha, A.N. Genotoxic and cytotoxic potential of titanium dioxide (TiO2) nanoparticles on fish
cells in vitro. Ecotoxicology 2008, 17, 410–420. [CrossRef] [PubMed]
47. Gottardo, S.; Quiros-Pesudo, L.; Totaro, S.; Riego-Sintes, J.; Crutzen, H. NANoREG Harmonised Terminology
for Environmental Health and Safety Assessment of Nanomaterials; Publications Office of the European Union:
Rue Mercier, Luxembourg, 2016.
48. Naha, P.C.; Casey, A.; Tenuta, T.; Lynch, I.; Dawson, K.A.; Byrne, H.J.; Davoren, M. Preparation,
characterization of NIPAM and NIPAM/BAM copolymer nanoparticles and their acute toxicity testing using
an aquatic test battery. Aquat. Toxicol. 2009, 92, 146–154. [CrossRef] [PubMed]
49. Naha, P.C.; Davoren, M.; Casey, A.; Byrne, H.J. An ecotoxicological study of poly(amidoamine)
dendrimers-toward quantitative structure activity relationships. Environ. Sci. Technol. 2009, 43, 6864–6869.
[CrossRef] [PubMed]
50. Stoeger, T.; Takenaka, S.; Frankenberger, B.; Ritter, B.; Karg, E.; Maier, K.; Schulz, H.; Schmid, O. Deducing
in vivo toxicity of combustion-derived nanoparticles from a cell-free oxidative potency assay and metabolic
activation of organic compounds. Environ. Health Perspect. 2009, 117, 54–60. [CrossRef] [PubMed]
51. Bouwmeester, H.; Lynch, I.; Marvin, H.J.; Dawson, K.A.; Berges, M.; Braguer, D.; Byrne, H.J.; Casey, A.;
Chambers, G.; Clift, M.J.; et al. Minimal analytical characterization of engineered nanomaterials needed for
hazard assessment in biological matrices. Nanotoxicology 2011, 5, 1–11. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 338 14 of 18
52. Nel, A.; Xia, T.; Madler, L.; Li, N. Toxic potential of materials at the nanolevel. Science 2006, 311, 622–627.
[CrossRef] [PubMed]
53. Xia, T.; Kovochich, M.; Brant, J.; Hotze, M.; Sempf, J.; Oberley, T.; Sioutas, C.; Yeh, J.I.; Wiesner, M.R.; Nel, A.E.
Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according
to an oxidative stress paradigm. Nano Lett. 2006, 6, 1794–1807. [CrossRef] [PubMed]
54. Rahman, I. Regulation of nuclear factor-kappa B, activator protein-1, and glutathione levels by tumor
necrosis factor-alpha and dexamethasone in alveolar epithelial cells. Biochem. Pharmacol. 2000, 60, 1041–1049.
[CrossRef]
55. Lanone, S.; Boczkowski, J. Biomedical applications and potential health risks of nanomaterials: Molecular
mechanisms. Curr. Mol. Med. 2006, 6, 651–663. [CrossRef] [PubMed]
56. Park, E.J.; Park, K. Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo
and in vitro. Toxicol. Lett. 2009, 184, 18–25. [CrossRef] [PubMed]
57. Dobrovolskaia, M.A.; McNeil, S.E. Immunological properties of engineered nanomaterials. Nat. Nanotechnol.
2007, 2, 469–478. [CrossRef] [PubMed]
58. Wang, J.; Liu, Y.; Jiao, F.; Lao, F.; Li, W.; Gu, Y.; Li, Y.; Ge, C.; Zhou, G.; Li, B.; et al. Time-dependent
translocation and potential impairment on central nervous system by intranasally instilled TiO(2)
nanoparticles. Toxicology 2008, 254, 82–90. [CrossRef] [PubMed]
59. Srinageshwar, B.; Peruzzaro, S.; Andrews, M.; Johnson, K.; Hietpas, A.; Clark, B.; McGuire, C.; Petersen, E.;
Kippe, J.; Stewart, A.; et al. PAMAM Dendrimers Cross the Blood-Brain Barrier When Administered through
the Carotid Artery in C57BL/6J Mice. Int. J. Mol. Sci. 2017, 18, 628. [CrossRef] [PubMed]
60. Naha, P.C.; Chhour, P.; Cormode, D.P. Systematic in vitro toxicological screening of gold nanoparticles
designed for nanomedicine applications. Toxicol. In Vitro 2015, 29, 1445–1453. [CrossRef] [PubMed]
61. Nowack, B.; Bucheli, T.D. Occurrence, behavior and effects of nanoparticles in the environment. Environ.
Pollut. 2007, 150, 5–22. [CrossRef] [PubMed]
62. Baun, A.; Sorensen, S.N.; Rasmussen, R.F.; Hartmann, N.B.; Koch, C.B. Toxicity and bioaccumulation
of xenobiotic organic compounds in the presence of aqueous suspensions of aggregates of nano-C(60).
Aquat. Toxicol. 2008, 86, 379–387. [CrossRef] [PubMed]
63. Cheng, J.; Flahaut, E.; Cheng, S.H. Effect of carbon nanotubes on developing zebrafish (Danio rerio) embryos.
Environ. Toxicol. Chem. 2007, 26, 708–716. [CrossRef] [PubMed]
64. Lin, D.; Xing, B. Phytotoxicity of nanoparticles: Inhibition of seed germination and root growth. Environ.
Pollut. 2007, 150, 243–250. [CrossRef] [PubMed]
65. Lovern, S.B.; Klaper, R. Daphnia magna mortality when exposed to titanium dioxide and fullerene (C60)
nanoparticles. Environ. Toxicol. Chem. 2006, 25, 1132–1137. [CrossRef] [PubMed]
66. Lovern, S.B.; Strickler, J.R.; Klaper, R. Behavioral and physiological changes in Daphnia magna when exposed
to nanoparticle suspensions (titanium dioxide, nano-C60, and C60HxC70Hx). Environ. Sci. Technol. 2007, 41,
4465–4470. [CrossRef] [PubMed]
67. Smith, C.J.; Shaw, B.J.; Handy, R.D. Toxicity of single walled carbon nanotubes to rainbow trout, (Oncorhynchus
mykiss): Respiratory toxicity, organ pathologies, and other physiological effects. Aquat. Toxicol. 2007, 82, 94–109.
[CrossRef] [PubMed]
68. Zhu, Y.; Zhao, Q.; Li, Y.; Cai, X.; Li, W. The interaction and toxicity of multi-walled carbon nanotubes with
Stylonychia mytilus. J. Nanosci. Nanotechnol. 2006, 6, 1357–1364. [CrossRef] [PubMed]
69. Handy, R.D.; van den Brink, N.; Chappell, M.; Muhling, M.; Behra, R.; Dusinska, M.; Simpson, P.; Ahtiainen, J.;
Jha, A.N.; Seiter, J.; et al. Practical considerations for conducting ecotoxicity test methods with manufactured
nanomaterials: What have we learnt so far? Ecotoxicology 2012, 21, 933–972. [CrossRef] [PubMed]
70. Heinlaan, M.; Ivask, A.; Blinova, I.; Dubourguier, H.C.; Kahru, A. Toxicity of nanosized and bulk ZnO,
CuO and TiO2 to bacteria Vibrio fischeri and crustaceans Daphnia magna and Thamnocephalus platyurus.
Chemosphere 2008, 71, 1308–1316. [CrossRef] [PubMed]
71. Mortimer, M.; Kasemets, K.; Heinlaan, M.; Kurvet, I.; Kahru, A. High throughput kinetic Vibrio fischeri
bioluminescence inhibition assay for study of toxic effects of nanoparticles. Toxicol. In Vitro 2008, 22, 1412–1417.
[CrossRef] [PubMed]
72. Naha, P.C.; Byrne, H.J. Generation of intracellular reactive oxygen species and genotoxicity effect to exposure
of nanosized polyamidoamine (PAMAM) dendrimers in PLHC-1 cells in vitro. Aquat. Toxicol. 2013, 132–133,
61–72. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 338 15 of 18
73. Glomstad, B.; Altin, D.; Sorensen, L.; Liu, J.; Jenssen, B.M.; Booth, A.M. Carbon Nanotube Properties
Influence Adsorption of Phenanthrene and Subsequent Bioavailability and Toxicity to Pseudokirchneriella
subcapitata. Environ. Sci. Technol. 2016, 50, 2660–2668. [CrossRef] [PubMed]
74. Sanchis, J.; Olmos, M.; Vincent, P.; Farre, M.; Barcelo, D. New Insights on the Influence of Organic
Co-Contaminants on the Aquatic Toxicology of Carbon Nanomaterials. Environ. Sci. Technol. 2016, 50, 961–969.
[CrossRef] [PubMed]
75. Fraser, T.W.; Reinardy, H.C.; Shaw, B.J.; Henry, T.B.; Handy, R.D. Dietary toxicity of single-walled carbon
nanotubes and fullerenes (C60) in rainbow trout (Oncorhynchus mykiss). Nanotoxicology 2011, 5, 98–108.
[CrossRef] [PubMed]
76. Huk, A.; Izak-Nau, E.; Reidy, B.; Boyles, M.; Duschl, A.; Lynch, I.; Dusinska, M. Is the toxic potential of
nanosilver dependent on its size? Part. Fibre Toxicol. 2014, 11, 65. [CrossRef] [PubMed]
77. Goncalves, S.P.; Strauss, M.; Delite, F.S.; Clemente, Z.; Castro, V.L.; Martinez, D.S. Activated carbon from
pyrolysed sugarcane bagasse: Silver nanoparticle modification and ecotoxicity assessment. Sci. Total Environ.
2016, 565, 833. [CrossRef] [PubMed]
78. Ramskov, T.; Forbes, V.E.; Gilliland, D.; Selck, H. Accumulation and effects of sediment-associated silver
nanoparticles to sediment-dwelling invertebrates. Aquat. Toxicol. 2015, 166, 96–105. [CrossRef] [PubMed]
79. Oprsal, J.; Blaha, L.; Pouzar, M.; Knotek, P.; Vlcek, M.; Hrda, K. Assessment of silver nanoparticle toxicity
for common carp (Cyprinus carpio) fish embryos using a novel method controlling the agglomeration in the
aquatic media. Environ. Sci. Pollut. Res. Int. 2015, 22, 19124–19132. [CrossRef] [PubMed]
80. Lee, C.C.; MacKay, J.A.; Frechet, J.M.; Szoka, F.C. Designing dendrimers for biological applications.
Nat. Biotechnol. 2005, 23, 1517–1526. [CrossRef] [PubMed]
81. Sevenson, S.; Tomalia, D.A. Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev.
2012, 64, 102–115. [CrossRef]
82. Boas, U.; Karlsson, A.J.; de Waal, B.F.; Meijer, E.W. Synthesis and properties of new thiourea-functionalized
poly(propylene imine) dendrimers and their role as hosts for urea functionalized guests. J. Org. Chem. 2001,
66, 2136–2145. [CrossRef] [PubMed]
83. Jansen, J.; Meijer, E.W.; de Brabander-van den Berg, E.M. The Dendritic Box: Shape-Selective Liberation of
Encapsulated Guests. J. Am. Chem. Soc. 1995, 117, 4417–4418. [CrossRef]
84. Jansen, J.F.; de Brabander-van den Berg, E.M.; Meijer, E.W. Encapsulation of guest molecules into a dendritic
box. Science 1994, 266, 1226–1229. [CrossRef] [PubMed]
85. D'Emanuele, A.; Attwood, D. Dendrimer-drug interactions. Adv. Drug Deliv. Rev. 2005, 57, 2147–2162.
[CrossRef] [PubMed]
86. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57, 2215–2237.
[CrossRef] [PubMed]
87. Svenson, S.; Tomalia, D.A. Dendrimers in biomedical applications—Reflections on the field. Adv. Drug Deliv. Rev.
2005, 57, 2106–2129. [CrossRef] [PubMed]
88. Venuganti, V.V.; Perumal, O.P. Effect of poly(amidoamine) (PAMAM) dendrimer on skin permeation of
5-fluorouracil. Int. J. Pharm. 2008, 361, 230–238. [CrossRef] [PubMed]
89. Kannan, R.M.; Nance, E.; Kannan, S.; Tomalia, D.A. Emerging concepts in dendrimer-based nanomedicine:
From design principles to clinical applications. J. Intern. Med. 2014, 276, 579–617. [CrossRef] [PubMed]
90. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy:
Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46,
6387–6392. [PubMed]
91. Gillies, E.R.; Frechet, J.M. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 2005, 10,
35–43. [CrossRef]
92. Miyano, T.; Wijagkanalan, W.; Kawakami, S.; Yamashita, F.; Hashida, M. Anionic amino acid dendrimer-
trastuzumab conjugates for specific internalization in HER2-positive cancer cells. Mol. Pharm. 2010, 7,
1318–1327. [CrossRef] [PubMed]
93. Shukla, R.; Thomas, T.P.; Desai, A.M.; Kotlyar, A.; Park, S.J.; Baker, J.R. HER2 specific delivery of methotrexate
by dendrimer conjugated anti-HER2 mAb. Nanotechnology 2008, 19, 295102. [CrossRef] [PubMed]
94. Shukla, R.; Thomas, T.P.; Peters, J.L.; Desai, A.M.; Kukowska-Latallo, J.; Patri, A.K.; Kotlyar, A.; Baker, J.R., Jr.
HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug. Chem. 2006, 17,
1109–1115. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 338 16 of 18
95. Wu, G.; Barth, R.F.; Yang, W.; Kawabata, S.; Zhang, L.; Green-Church, K. Targeted delivery of methotrexate
to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer
bioconjugates. Mol. Cancer Ther. 2006, 5, 52–59. [CrossRef] [PubMed]
96. Yang, W.; Wu, G.; Barth, R.F.; Swindall, M.R.; Bandyopadhyaya, A.K.; Tjarks, W.; Tordoff, K.; Moeschberger, M.;
Sferra, T.J.; Binns, P.J.; et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive
gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 2008, 14, 883–891. [CrossRef] [PubMed]
97. Rajananthanan, P.; Attard, G.S.; Sheikh, N.A.; Morrow, W.J. Evaluation of novel aggregate structures as
adjuvants: Composition, toxicity studies and humoral responses. Vaccine 1999, 17, 715–730. [CrossRef]
98. Hulikova, K.; Benson, V.; Svoboda, J.; Sima, P.; Fiserova, A. N-Acetyl-D-glucosamine-coated polyamidoamine
dendrimer modulates antibody formation via natural killer cell activation. Int. Immunopharmacol. 2009, 9,
792–799. [CrossRef] [PubMed]
99. Wiener, E.C.; Brechbiel, M.W.; Brothers, H.; Magin, R.L.; Gansow, O.A.; Tomalia, D.A.; Lauterbur, P.C.
Dendrimer-based metal chelates: A new class of magnetic resonance imaging contrast agents. Magn. Reson. Med.
1994, 31, 1–8. [CrossRef] [PubMed]
100. Konda, S.D.; Aref, M.; Brechbiel, M.; Wiener, E.C. Development of a tumor-targeting MR contrast agent
using the high-affinity folate receptor: Work in progress. Investig. Radiol. 2000, 35, 50–57. [CrossRef]
101. OECD. Series on the Safety of Manufactured Nanomaterials. No. 27 List of Manufactured Nanomaterials and
List of Endpoints for Phase One of the Sponsorship Programme for the Testing of Manufactured Nanomaterials:
Revision. Available online: http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/
jm/mono%282010%2946&doclanguage=en (accessed on 12 Ferubuary 2018).
102. Mukherjee, S.P.; Byrne, H.J. Polyamidoamine dendrimer nanoparticle cytotoxicity, oxidative stress, caspase
activation and inflammatory response: Experimental observation and numerical simulation. Nanomedicine
2013, 9, 202–211. [CrossRef] [PubMed]
103. Mukherjee, S.P.; Davoren, M.; Byrne, H.J. In vitro mammalian cytotoxicological study of PAMAM
dendrimers—Towards quantitative structure activity relationships. Toxicol. In Vitro 2010, 24, 169–177. [CrossRef]
[PubMed]
104. Mukherjee, S.P.; Lyng, F.M.; Garcia, A.; Davoren, M.; Byrne, H.J. Mechanistic studies of in vitro cytotoxicity of
poly(amidoamine) dendrimers in mammalian cells. Toxicol. Appl. Pharmacol. 2010, 248, 259–268. [CrossRef]
[PubMed]
105. Lee, J.H.; Cha, K.E.; Kim, M.S.; Hong, H.W.; Chung, D.J.; Ryu, G.; Myung, H. Nanosized polyamidoamine
(PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction. Toxicol. Lett. 2009, 190,
202–207. [CrossRef] [PubMed]
106. Labieniec, M.; Gabryelak, T. Preliminary biological evaluation of poli(amidoamine) (PAMAM) dendrimer
G3.5 on selected parameters of rat liver mitochondria. Mitochondrion 2008, 8, 305–312. [CrossRef] [PubMed]
107. Hong, S.; Bielinska, A.U.; Mecke, A.; Keszler, B.; Beals, J.L.; Shi, X.; Balogh, L.; Orr, B.G.; Baker, J.R., Jr.;
Banaszak Holl, M.M. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells:
Hole formation and the relation to transport. Bioconjug. Chem. 2004, 15, 774–782. [CrossRef] [PubMed]
108. Leroueil, P.R.; Berry, S.A.; Duthie, K.; Han, G.; Rotello, V.M.; McNerny, D.Q.; Baker, J.R., Jr.; Orr, B.G.;
Holl, M.M. Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Lett.
2008, 8, 420–424. [CrossRef] [PubMed]
109. Leroueil, P.R.; Hong, S.; Mecke, A.; Baker, J.R., Jr.; Orr, B.G.; Banaszak Holl, M.M. Nanoparticle interaction
with biological membranes: Does nanotechnology present a Janus face? Acc. Chem. Res. 2007, 40, 335–342.
[CrossRef] [PubMed]
110. Malik, N.; Wiwattanapatapee, R.; Klopsch, R.; Lorenz, K.; Frey, H.; Weener, J.W.; Meijer, E.W.; Paulus, W.;
Duncan, R. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary
studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Controll. Release 2000,
65, 133–148. [CrossRef]
111. Roberts, J.C.; Bhalgat, M.K.; Zera, R.T. Preliminary biological evaluation of polyamidoamine (PAMAM)
Starburst dendrimers. J. Biomed. Mater. Res. 1996, 30, 53–65. [CrossRef]
112. Bodewein, L.; Schmelter, F.; Di Fiore, S.; Hollert, H.; Fischer, R.; Fenske, M. Differences in toxicity of anionic
and cationic PAMAM and PPI dendrimers in zebrafish embryos and cancer cell lines. Toxicol. Appl. Pharmacol.
2016, 305, 83–92. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 338 17 of 18
113. Wang, W.; Xiong, W.; Zhu, Y.; Xu, H.; Yang, X. Protective effect of PEGylation against poly(amidoamine)
dendrimer-induced hemolysis of human red blood cells. J. Biomed. Mater. Res. Part B Appl. Biomater. 2010, 93,
59–64. [CrossRef] [PubMed]
114. Khalid, H.; Mukherjee, S.P.; O'Neill, L.; Byrne, H.J. Structural dependence of in vitro cytotoxicity, oxidative
stress and uptake mechanisms of poly(propylene imine) dendritic nanoparticles. J. Appl. Toxicol. 2016, 36,
464–473. [CrossRef] [PubMed]
115. Maher, M.A.; Naha, P.C.; Mukherjee, S.P.; Byrne, H.J. Numerical simulations of in vitro nanoparticle
toxicity—The case of poly(amido amine) dendrimers. Toxicol. In Vitro 2014, 28, 1449–1460. [CrossRef] [PubMed]
116. Bertero, A.; Boni, A.; Gemmi, M.; Gagliardi, M.; Bifone, A.; Bardi, G. Surface functionalisation regulates
polyamidoamine dendrimer toxicity on blood-brain barrier cells and the modulation of key inflammatory
receptors on microglia. Nanotoxicology 2014, 8, 158–168. [CrossRef] [PubMed]
117. Albertazzi, L.; Gherardini, L.; Brondi, M.; Sulis Sato, S.; Bifone, A.; Pizzorusso, T.; Ratto, G.M.; Bardi, G.
In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their
surface chemistry. Mol. Pharm. 2013, 10, 249–260. [CrossRef] [PubMed]
118. Feliu, N.; Kohonen, P.; Ji, J.; Zhang, Y.; Karlsson, H.L.; Palmberg, L.; Nystrom, A.; Fadeel, B. Next-generation
sequencing reveals low-dose effects of cationic dendrimers in primary human bronchial epithelial cells.
ACS Nano 2015, 9, 146–163. [CrossRef] [PubMed]
119. Ryman-Rasmussen, J.P.; Riviere, J.E.; Monteiro-Riviere, N.A. Surface coatings determine cytotoxicity and
irritation potential of quantum dot nanoparticles in epidermal keratinocytes. J. Investig. Dermatol. 2007, 127,
143–153. [CrossRef] [PubMed]
120. Lazniewska, J.; Milowska, K.; Zablocka, M.; Mignani, S.; Caminade, A.M.; Majoral, J.P.; Bryszewska, M.;
Gabryelak, T. Mechanism of Cationic Phosphorus Dendrimer Toxicity against Murine Neural Cell Lines.
Mol. Pharm. 2013, 10, 3484–3496. [CrossRef] [PubMed]
121. Ciolkowski, M.; Rozanek, M.; Bryszewska, M.; Klajnert, B. The influence of PAMAM dendrimers surface
groups on their interaction with porcine pepsin. Biochim. Biophys. Acta 2013, 1834, 1982–1987. [CrossRef]
[PubMed]
122. Wang, L.; Wang, Z.; Ma, G.; Lin, W.; Chen, S. Reducing the cytotoxity of poly(amidoamine) dendrimers by
modification of a single layer of carboxybetaine. Langmuir 2013, 29, 8914–8921. [CrossRef] [PubMed]
123. Janaszewska, A.; Ciolkowski, M.; Wrobel, D.; Petersen, J.F.; Ficker, M.; Christensen, J.B.; Bryszewska, M.;
Klajnert, B. Modified PAMAM dendrimer with 4-carbomethoxypyrrolidone surface groups reveals negligible
toxicity against three rodent cell-lines. Nanomedicine 2013, 9, 461–464. [CrossRef] [PubMed]
124. Ciolkowski, M.; Petersen, J.F.; Ficker, M.; Janaszewska, A.; Christensen, J.B.; Klajnert, B.; Bryszewska, M.
Surface modification of PAMAM dendrimer improves its biocompatibility. Nanomedicine 2012, 8, 815–817.
[CrossRef] [PubMed]
125. Kolhatkar, R.B.; Kitchens, K.M.; Swaan, P.W.; Ghandehari, H. Surface acetylation of polyamidoamine
(PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug. Chem.
2007, 18, 2054–2060. [CrossRef] [PubMed]
126. Demaurex, N. pH Homeostasis of cellular organelles. News Physiol. Sci. 2002, 17, 1–5. [CrossRef] [PubMed]
127. Seib, F.P.; Jones, A.T.; Duncan, R. Comparison of the endocytic properties of linear and branched PEIs, and
cationic PAMAM dendrimers in B16f10 melanoma cells. J. Controll. Release 2007, 117, 291–300. [CrossRef]
[PubMed]
128. Lee, I.; Athey, B.D.; Wetzel, A.W.; Meixner, W.; Baker, J.R. Structural molecular dynamics studies on
polyamidoamine dendrimers for a therapeutic application: Effects of pH and generation. Macromolecules
2002, 35, 4510–4520. [CrossRef]
129. Perumal, O.P.; Inapagolla, R.; Kannan, S.; Kannan, R.M. The effect of surface functionality on cellular
trafficking of dendrimers. Biomaterials 2008, 29, 3469–3476. [CrossRef] [PubMed]
130. Albertazzi, L.; Serresi, M.; Albanese, A.; Beltram, F. Dendrimer Internalization and Intracellular Trafficking
in Living Cells. Mol. Pharm. 2010, 7, 680–688. [CrossRef] [PubMed]
131. Feliu, N.; Walter, M.V.; Montanez, M.I.; Kunzmann, A.; Hult, A.; Nystrom, A.; Malkoch, M.; Fadeel, B.
Stability and biocompatibility of a library of polyester dendrimers in comparison to polyamidoamine
dendrimers. Biomaterials 2012, 33, 1970–1981. [CrossRef] [PubMed]
132. Cheng, Y.; Zhao, L.; Li, Y.; Xu, T. Design of biocompatible dendrimers for cancer diagnosis and therapy:
Current status and future perspectives. Chem. Soc. Rev. 2011, 40, 2673–2703. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 338 18 of 18
133. Maher, M.A.; Byrne, H.J. Modification of the in vitro uptake mechanism and antioxidant levels in HaCaT
cells and resultant changes to toxicity and oxidative stress of G4 and G6 poly(amidoamine) dendrimer
nanoparticles. Anal. Bioanal. Chem. 2016, 408, 5295–5307. [CrossRef] [PubMed]
134. Girard, P.M.; Graindorge, D.; Smirnova, V.; Rigolet, P.; Francesconi, S.; Scanlon, S.; Sage, E. Oxidative stress
in mammalian cells impinges on the cysteines redox state of human XRCC3 protein and on its cellular
localization. PLoS ONE 2013, 8, e75751. [CrossRef] [PubMed]
135. He, Y.Y.; Huang, J.L.; Ramirez, D.C.; Chignell, C.F. Role of reduced glutathione efflux in apoptosis of
immortalized human keratinocytes induced by UVA. J. Biol. Chem. 2003, 278, 8058–8064. [CrossRef] [PubMed]
136. Madesh, M.; Benard, O.; Balasubramanian, K.A. Glutathione modulates lipid composition of human colon
derived HT-29 cells. Int. J. Biochem. Cell Biol. 1998, 30, 1345–1352. [CrossRef]
137. Tobi, S.E.; Paul, N.; McMillan, T.J. Glutathione modulates the level of free radicals produced in
UVA-irradiated cells. J. Photochem. Photobiol. B 2000, 57, 102–112. [CrossRef]
138. Hipkiss, A.R. Carnosine and its possible roles in nutrition and health. Adv. Food Nutr. Res. 2009, 57, 87–154.
[PubMed]
139. Guarnieri, D.; Sabella, S.; Muscetti, O.; Belli, V.; Malvindi, M.A.; Fusco, S.; De Luca, E.; Pompa, P.P.;
Netti, P.A. Transport across the cell-membrane dictates nanoparticle fate and toxicity: A new paradigm in
nanotoxicology. Nanoscale 2014, 6, 10264–10273. [CrossRef] [PubMed]
140. Jones, C.F.; Campbell, R.A.; Brooks, A.E.; Assemi, S.; Tadjiki, S.; Thiagarajan, G.; Mulcock, C.; Weyrich, A.S.;
Brooks, B.D.; Ghandehari, H.; et al. Cationic PAMAM dendrimers aggressively initiate blood clot formation.
ACS Nano 2012, 6, 9900–9910. [CrossRef] [PubMed]
141. Greish, K.; Thiagarajan, G.; Herd, H.; Price, R.; Bauer, H.; Hubbard, D.; Burckle, A.; Sadekar, S.; Yu, T.;
Anwar, A.; et al. Size and surface charge significantly influence the toxicity of silica and dendritic
nanoparticles. Nanotoxicology 2012, 6, 713–723. [CrossRef] [PubMed]
142. Wang, F.; Cai, X.; Su, Y.; Hu, J.; Wu, Q.; Zhang, H.; Xiao, J.; Cheng, Y. Reducing cytotoxicity while improving
anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation. Acta Biomater.
2012, 8, 4304–4313. [CrossRef] [PubMed]
143. Sun, Y.; Guo, F.; Zou, Z.; Li, C.; Hong, X.; Zhao, Y.; Wang, C.; Wang, H.; Liu, H.; Yang, P.; et al.
Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in
mice. Part. Fibre Toxicol. 2015, 12, 4. [CrossRef] [PubMed]
144. Durocher, I.; Girard, D. In vivo proinflammatory activity of generations 0-3 (G0-G3) polyamidoamine
(PAMAM) nanoparticles. Inflamm. Res. 2016, 65, 745–755. [CrossRef] [PubMed]
145. Heiden, T.C.; Dengler, E.; Kao, W.J.; Heideman, W.; Peterson, R.E. Developmental toxicity of low generation
PAMAM dendrimers in zebrafish. Toxicol. Appl. Pharmacol. 2007, 225, 70–79. [CrossRef] [PubMed]
146. Lesniak, W.G.; Mishra, M.K.; Jyoti, A.; Balakrishnan, B.; Zhang, F.; Nance, E.; Romero, R.; Kannan, S.;
Kannan, R.M. Biodistribution of fluorescently labeled PAMAM dendrimers in neonatal rabbits: Effect of
neuroinflammation. Mol. Pharm. 2013, 10, 4560–4571. [CrossRef] [PubMed]
147. Thiagarajan, G.; Sadekar, S.; Greish, K.; Ray, A.; Ghandehari, H. Evidence of oral translocation of anionic
G6.5 dendrimers in mice. Mol. Pharm. 2013, 10, 988–998. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
